Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 25;54(3):34.
doi: 10.3390/medicina54030034.

Risk Factors, Co-Morbidities and Treatment of In-Hospital Patients with Atrial Fibrillation in Bulgaria

Affiliations

Risk Factors, Co-Morbidities and Treatment of In-Hospital Patients with Atrial Fibrillation in Bulgaria

Stefan Naydenov et al. Medicina (Kaunas). .

Abstract

Background and objectives: Atrial fibrillation (AF) is the most common arrhythmia worldwide and a major risk factor for cardiovascular complications. Our study aimed to investigate the prevalence, risk factors, demographics, co-morbidities and treatment of AF among in-hospital Bulgarian patients.

Materials and methods: A cross-sectional study including 1027 consecutive patients (n = 516, 50.2% males) with a mean age of 67.6 ± 11.3 years, hospitalized for any reason from 1 May until 31 December 2016 in one of the largest internal clinics in Bulgaria, was carried out.

Results: Atrial fibrillation was diagnosed in 634 (61.7%) patients. The prevalence of modifiable AF risk factors was as follows: heart failure, 98.9%; arterial hypertension (HTN), 93.5%; valvular heart disease, 40.9%; chronic lung disease, 26.7%; type 2 diabetes mellitus, 24.9%; thyroid disease, 16.9%; and ischemic heart disease, 11.2%. Univariate logistic regression analysis identified the following risk factors with strongest impact on AF: left ventricular ejection fraction <40% (odds ratio (OR) = 1.951, 95% confidence interval (CI) 1.208⁻3.151), valvular heart disease (OR = 1.926, 95% CI 1.134⁻3.862), left ventricular ejection fraction 40⁻49% (OR = 1.743, 95% CI 1.248⁻3.017), HTN (OR = 1.653, 95% CI 1.092⁻3.458). History of ischemic stroke was present in 14.4% of the patients with AF. Oral antithrombotic drugs were prescribed to 85.7%: direct oral anticoagulants to 37.9%, vitamin K antagonists to 43.2%, and antiplatelets to 4.6%. Heart rate control medications and antiarrhythmics were prescribed to 75.4% and 40.2%, respectively.

Conclusions: Atrial fibrillation was highly prevalent among our study population. Reduced and mid-range left ventricular ejection fraction, valvular heart disease, and HTN were the risk factors with the strongest association with AF. Although a large number of our AF patients were administered antithrombotic treatment, the prescription rate of oral anticoagulants should be further improved.

Keywords: atrial; embolic; fibrillation; in-hospital; prevention; risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Gender differences in the types of AF; Independent χ2-test was used for comparison of the prevalence of different AF types in both genders; AF—atrial fibrillation; LS—long-standing persistent; p—level of significance.

Similar articles

Cited by

References

    1. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar A., Casadei B., Castella M., Diener H.C., Heidbuchel H., Hendriks J. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed
    1. Chugh S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., Gillum R.F., Kim Y.H., McAnulty J.H., Zheng Z.J., et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847. doi: 10.1161/CIRCULATIONAHA.113.005119. - DOI - PMC - PubMed
    1. Colilla S., Crow A., Petkun W., Singer D., Simon T., Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am. J. Cardiol. 2013;112:1142–1147. doi: 10.1016/j.amjcard.2013.05.063. - DOI - PubMed
    1. Heeringa J., van der Kuip D., Hofman A., Kors J., van Herpen G., Stricker B.H.C., Stijnen T., Lip G.Y., Witteman J.C. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur. Heart J. 2006;27:949–953. doi: 10.1093/eurheartj/ehi825. - DOI - PubMed
    1. Krijthe B., Kunst A., Benjamin E., Lip G., Franco O., Hofman A., Witteman J.C., Stricker B.H., Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 2013;34:2746–2751. doi: 10.1093/eurheartj/eht280. - DOI - PMC - PubMed

MeSH terms